Adipotide (FTPP)
Also known as Adipotide · FTPP · Prohibitin-targeting peptide · TP-01
New
Reconstitution & dosing guide
2 mg · 5 mg · 10 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Adipotide/FTTP (APE10) · Not in current stock
$80 / vial
2mg x 10 vials
Adipotide/FTTP (APE2) · Not in current stock
$35 / vial
5mg x 10 vials
Adipotide/FTTP (APE5) · Not in current stock
$50 / vial
Prices per vial · Research use only · Not medical advice.
Experimental peptidomimetic that targets prohibitin on white adipose vasculature, designed to trigger apoptosis of fat-blood-supply cells and reduce fat mass in animal models.
How to picture it
Designed to bind prohibitin on white-fat blood vessels and deliver a kill signal to those vessels, starving fat tissue in animal research. Picture cutting the supply lines to fat pads — dramatic in models, with equally serious safety scrutiny. Listed for scientific completeness as high-risk experimental biology, not casual interest.
Research focus & benefits
- Adipose vasculature targeting research
- Experimental fat-regression model studies
- High-risk experimental biology reference
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2 class FTPP) was developed to bind a white-fat vascular marker and deliver a pro-apoptotic motif, starving adipocytes. Monkey and mouse studies showed fat loss and metabolic improvements, but kidney toxicity signals slowed translation. Still appears in research catalogs.
Mechanism
Homes to prohibitin-expressing adipose vasculature; pro-apoptotic domain disrupts mitochondrial membranes of targeted endothelial cells leading to white fat regression.
Research uses
- Obese mouse and monkey fat-reduction studies
- Targeted adipose vasculature ablation research
- Metabolic improvement secondary endpoints
Research dosing notes
Animal study mg/kg schedules only. Human research dose not established; renal monitoring was a development concern.
Half-life / kinetics
Research-dependent
Common research routes
Reported considerations
- Renal toxicity signals in development
- Injection reactions
- Unknown human safety
Contraindications / cautions
- Kidney disease
- Pregnancy
- Dehydration risk contexts
Common research stacks
- AOD-9604
- GLP-1 agonists (different mechanism)
Legal / access note
Experimental. Not approved for weight loss. Renal safety concerns historically noted.